Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis

In a study of 13 myelofibrosis patients, 45% of 11 evaluable patients had a more than 10% spleen reduction. Credit: Gorodenkoff / Shutterstock.com.



  • Cellenkos FDA status